Have you been diagnosed with non-small cell lung cancer? Have you already been treated with an anti PDL-1 therapy and chemotherapy? If so, you may be able to take part in a research study looking to compare the safety and effectiveness of the investigational drug RMC-6236 to docetaxel.

We're studying how parts of your daily routine, like exercise, sitting, and sleep, influence heart health in those who have survived endometrial cancer. Understanding this could lead to better lifestyle advice for survivors like you. If you join, you'll have two check-ups during your normal clinic visits. We'll check your blood pressure and blood vessels using a simple cuff similar to the one for blood pressure. We'll also look at your body makeup and ask you to do some quick physical tests like balancing and walking, as well as squeezing a grip tool. You'll also wear movement trackers on your hand and thigh for a week and fill out some surveys. Your participation could help improve health advice for others in your situation.

The purpose of this research is to learn whether the investigational study drug BMS-986504 works to treat metastatic (cancer that has spread in the body) pancreatic ductal adenocarcinoma (PDAC) when combined with standard chemotherapy in participants with homozygous MTAP deletion or MTAP loss, who have not previously received treatment for metastatic PDAC.

This study is being conducted to see how well a study drug called ponsegromab works and if it might improve health and quality of life compared to a placebo in adults who have cachexia (a condition causing significant unintentional weight loss and muscle wasting) and metastatic pancreatic cancer, for which they receive initial chemotherapy.

We're doing this study to understand how a type of genetic material called DNA in the blood changes in people with a specific type of cancer that has spread to only a few places in the body. By looking at how this DNA behaves before and after cancer treatment, including radiation, we aim to learn more about how the cancer responds. To do this, we'll collect blood and tumor samples from you to analyze what's happening. This could help in better understanding and improving cancer treatments for others in the future.

Have you been diagnosed with Leukemia? Do you have a functioning kidney, liver, and cardiac organ? If so, you may be able to participate in a study on a new drug called Ziftomenib. We want to find out if it hooking their interest enough to click on the link to is safe for people with Leukemia. Compensation provided.

We're looking for people with bladder cancer to join a study on a new radiation treatment. If you have bladder cancer, this study will tests if receiving higher doses of radiation in a shorter time, along with chemotherapy, works as well as standard treatments. Participating may help you avoid surgery to remove your bladder. It may also mean you finish treatment faster, which might fit better with your needs. Overall, by joining the study you can contribute to improving future bladder cancer care for you and others.

The purpose of this study is to see if etentamig is safe and to identify the optimal etentamig dose when combined with daratumumab in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for transplant.

Are you 18 years or older and diagnosed with HER2+, clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 breast cancer and prior to surgery did you received chemotherapy in combination with Trastuzumab for a minimum of 12 weeks? If so, you may be eligible for a research study evaluating the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2-targeted medications at reducing the risk of breast cancer coming back or death in patients.

We're testing a new treatment called AVZO-103, alone and with another drug, to find the safest and most effective dose. We want to see if this combination can help treat advanced solid tumors. We're also studying how your body processes and reacts to AVZO-103 to learn who might benefit most from it.